• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Painful Diabetic Neuropathy Treatment: A Guideline Topline

Slideshow

Painful diabetic neuropathy (PDN) affects more than 16% of patients with diabetes and is the most common form of peripheral neuropathy.

The American Academy of Neurology recently issued a guideline on oral and topical treatments for PDN published in the journal Neurology, which updated its 2011 guidance. Authors searched the literature from January 2008 to April 2020 using a structured review process to classify the evidence and develop practice recommendations. In the slides below, find a concise summary of the guideline.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort / image credit ASCVD: ©Rasi/stock.adobe.com

Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort

April 16th 2024
Article

Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Novel Antiobesity Drug Improves Body Composition, Bone Mineral Content in Phase 2 Study / image credit escape obesity: ©Siberian Art/stock.adobe.com

Novel Antiobesity Drug Significantly Improves Body Composition, Bone Mineral Content in Phase 2 Study

April 12th 2024
Article

LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.

Obesity & Pain Management: A Primary Viewpoints Podcast

Obesity & Pain Management: A Primary Viewpoints Podcast

April 27th 2023
Podcast

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

Atogepant vs Rimegepant for Migraine Prevention: Daily Dose / image credit: ©New Africa/AdobeStock

Atogepant vs Rimegepant for Migraine Prevention: Daily Dose

April 11th 2024
Article

Your daily dose of the clinical news you may have missed.

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D / image Mikhail Kosiborod, MD St Luke's Mid America Heart institute

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D

April 8th 2024
Article

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

© 2024 MJH Life Sciences

All rights reserved.